Sava Technologies has closed a $36 million Series B led by Ascensia Diabetes Care, which will also commercialize its interstitial fluid microsensor in Europe following anticipated CE approval in 18 to 24 months. The sensor sits roughly a tenth as deep as a conventional continuous glucose monitor and matched a leading commercial CGM over ten days in 46 people with insulin-dependent diabetes. Its longer-term relevance lies in a platform designed to track multiple molecules continuously from a single wearable.
Key Points
- Ascensia leads $36m round and will distribute sensor across Europe
- Microsensor matched commercial CGM accuracy over ten days
- Platform targets multi-molecule tracking beyond glucose, including lactate and ketones
Longevity Analysis
Continuous metabolic data shifts the question from whether a value is abnormal to how a system behaves under real conditions — how fuel is handled after meals, during exertion, across sleep. A sensor capable of reading several molecules at once moves monitoring closer to the way energy production, hormonal signaling and recovery actually interact, rather than sampling one of them in isolation. The constraint is interpretive: a continuous lactate or ketone trace changes outcomes only when it triggers a specific, repeatable action, and that clinical vocabulary does not yet exist.
Original published by Longevity.Technology, by Eleanor Garth.